




2023 TASLC International Symposium on Treatment Advances in Lung Cancer



Chairman
James Yang



Co-Chairman
Chong-Jen Yu


Jan. 7th SAT
12:00-18:00

台大醫院癌醫中心分院5樓
台北市大安區基隆路三段155巷57號

Time	Topic	Speaker	Moderator
Satellite Symposium			
	Merck & Amgen		
12:00-12:40	Rare mutation management in NSCLC - MET and KRAS	Paul K. Paik	James Yang
	AZ		
12:40-13:20	The New Landscape in Resectable EGFR-mutant NSCLC Treatment	Karen Kelly	Gee-Chen Chang
Plenary Lecture I Lung cancer research in this challenging era			
13:30-13:40	Opening Address	James Yang	
13:40-13:55	IASLC, past, present and future	Karen Kelly	James Yang
13:55-14:20	Lung cancer clinical trials in Korea and development of Korean treatment guidelines	Myung-Ju Ahn	Jin-Yuan Shih
14:20-14:45	Lung cancer clinical trials in Japan and development of Japanese treatment guidelines	Hidehito Horinouchi	Chun-Liang Lai
14:45-15:00	Panel Discussion		
15:00-15:20	Coffee Break		
Plenary Lecture II Driver mutation-positive NSCLC, where are we now?			
15:20-15:45	20 years of EGFR mutant NSCLC treatment	Tetsuya Mitsudomi	Pan-Chyr Yang
15:45-16:10	Novel ALK and ROS1 inhibitors	Sai-Hong Ou	Ching-Liang Ho
16:10-16:35	EGFR and HER2 exon 20 insertion inhibitors	Chee Lee	Chien-Chung Lin
16:35-17:00	KRAS inhibitors, what is right and what is wrong?	Chiun Hsu / Chia-Chi (Josh) Lin	Kang-Yun Lee
17:00-17:15	Panel Discussion		
Satellite Symposium			
	Johnson & Johnson		
17:20-18:00	Expanding horizons for the targeted management of EGFR-mutant NSCLC	Myung-Ju Ahn	Chong-Jen Yu

Registration

Add to calendar



2023 TASLC International Symposium on Treatment Advances in Lung Cancer



Chairman
James Yang



Co-Chairman
Chong-Jen Yu

Jan. 8th SUN
08:20-15:15

台大醫院癌醫中心分院5樓
台北市大安區基隆路三段155巷57號

Time	Topic	Speaker	Moderator
Satellite Symposium			
MSD			
08:20-09:00	From long - term clinical follow up data to real world practice : How do we position immunotherapy in lung cancer treatment	Martin, Reck	Inn-Wen Chong
Plenary Lecture III Novel insight into driver mutation-positive NSCLC			
09:00-09:25	ADC and bispecific antibody in lung cancer treatment	Byoung-Chul Cho	Meng-Chih Lin
09:25-09:50	All about MET inhibitors	Paul K. Paik	Inn-Wen Chong
09:50-10:15	RET and NTRK inhibitors	Daniel Tan	Tsung-Ying Yang
10:15-10:30	Panel Discussion		
10:30-10:50	Coffee Break		
10:50-11:15	Pathologist's role in molecular diagnosis	Ming-Sound Tsao	Teh-Ying Chou
11:15-11:40	Liquid biopsy for NSCLC	Natasha Leighl	Chung-Kan Peng
11:40-12:05	Opportunity for proteogenomics-guided precision oncology in non-smoking lung cancer	Yu-Ju Chen	Gee-Chen Chang
12:05-12:15	Panel Discussion		
Luncheon Symposium			
Roche			
12:30-13:10	The clinical value of comprehensive genomic profiling and adjuvant immunotherapy in early stage lung cancer	Sai-Hong Ou	Chun-Liang Lai
Plenary Lecture IV: Immunotherapy moving forward			
13:10-13:35	Immunotherapy for advanced NSCLC, current evidence and future direction	Martin, Reck	Wen-Cheng Chang
13:35-14:00	Incorporation of systemic treatment in surgery in the era of personalized medicine	Young Tae Kim	Jin-Shing Chen
14:00-14:25	Perioperative immunotherapy and chemotherapy for NSCLC	Everett Vokes	James Yang
14:25-14:50	Transformative platform for future lung cancer care	Tony Mok	Chong-Jen Yu
14:50-15:05	Panel Discussion		
15:05-15:15	Concluding Address	James Yang	

Registration

Add to calendar